Ritika Dwivedi

Ritika Dwivedi, Ph.D. has a diverse work experience in the fields of biotechnology, molecular biology, and protein engineering. Ritika is currently working as a Principal Scientist at Intellia Therapeutics, Inc., where they focus on platform innovation and protein engineering. Prior to this, they served as a Senior Scientist at the same company.

Before joining Intellia Therapeutics, Inc., Ritika worked at Sana Biotechnology as a Senior Scientist/Associate Director, contributing to the development of engineered cells for medical purposes.

Their earlier experience includes a position as a Postdoctoral Research Scientist at The Broad Institute of MIT and Harvard, where they conducted research on protein engineering, drug discovery, and novel proteomics strategies. Ritika also obtained two patents during their time there.

Ritika's academic journey began with a Ph.D. in Biotechnology and Molecular Biology at the University of Alberta. Their research focused on studying pathogenic pathways in Campylobacter species and understanding protein glycosylation pathways. Ritika also worked as a researcher at GlycoNet, collaborating on various projects related to carbohydrate synthesis and vaccine development.

Furthermore, they served as a Research Assistant at Alberta Bovine Genomics and gained research experience as an Honors Program Researcher during their undergraduate studies at the University of Alberta.

Overall, Ritika Dwivedi's work experience showcases their expertise and contributions in the fields of biotechnology, protein engineering, and molecular biology.

Ritika Dwivedi, Ph.D. received their education in the field of Biotechnology and Molecular Biology. Ritika completed their Bachelor of Science degree at the University of Alberta from 2005 to 2009. Following this, they pursued their Doctor of Philosophy (PhD) from 2010 to 2015 at the same institution. In addition to their academic qualifications, they also hold certifications in "Being an Effective Team Member" and "Leading and Working in Teams" from LinkedIn, obtained in 2020.